Aptar appoints Gael Touya CEO effective Sept 1, 2026; Stephan Tanda to retire end-2026

Leadership change

Gael Touya will become President and CEO of AptarGroup on September 1, 2026; the Board will appoint him as a director that day. Stephan B. Tanda will remain as an advisor through the end of 2026 and retire from the Board by year‑end 2026.

Touya background

Touya has 30+ years at Aptar with roles across Europe, Asia and North America, including President of Aptar Pharma since 2018, President of Food + Beverage (now Aptar Closures), President Food + Beverage Europe, Vice President of Business Development for Skincare & Color Cosmetics, and P&L leadership in China and Japan; he holds a business degree from Excelia, an MBA from ESSEC and completed the Harvard Business School Advanced Management Program.

Pharma performance and strategy

Since 2018 Aptar Pharma delivered approximately 82% topline growth; the segment expanded its technologies and services to support development through commercialization, combined targeted acquisitions with organic development, added regulatory and clinical development capabilities, patient onboarding and digital health, and extended nasal/respiratory delivery into systemic applications and biologics.

Tanda tenure and financials

Since 2017 Aptar completed roughly 20 bolt‑on acquisitions (majority in Pharma), including Active Material Science in 2018; adjusted EBITDA margins rose from ~19% at year‑end 2017 to ~22% at year‑end 2025, adjusted EPS increased 67%, capital returned to shareholders grew ~100%, and Aptar recorded its 32nd consecutive annual dividend increase in 2025.